Natera Reports 52% Revenue Growth and Strong Demand in Genetic Testing Sector

Natera Reports Significant Growth in Genetic Testing Sector

Natera, Inc., a prominent player in the field of cell-free DNA and genetic testing, announces remarkable preliminary results for the fourth quarter and full year ending December 31, 2024. The company reports total revenues of approximately $472 million for Q4 2024, reflecting a substantial 52% increase from $311 million in Q4 2023. For the full year, Natera's revenue reaches approximately $1.7 billion, which marks a 56% rise compared to $1.1 billion in 2023. These figures underscore Natera's robust growth trajectory and solidify its position in the expanding market for genetic testing.

The surge in revenue is complemented by an impressive increase in the number of tests processed. Natera processes around 792,800 tests in Q4 2024, a 26.5% rise from 626,800 tests during the same quarter the previous year. This trend persists throughout the year, with approximately 3,064,600 tests processed, reflecting a 22.8% increase over the 2,496,100 tests conducted in 2023. Notably, the company achieves record performance in its flagship products—Panorama™, Prospera™, and Signatera™—indicating strong demand and expanding market recognition.

A standout area for Natera is its oncology testing segment, which exhibits remarkable growth. In Q4 2024, Natera processes around 150,800 oncology tests, a staggering 54.7% increase from 97,500 tests in Q4 2023. For the entire year, the company conducts approximately 528,200 oncology tests, up 54.9% from 341,000 in 2023. This growth not only illustrates the increasing reliance on genetic testing in oncology but also highlights Natera’s capability to meet the rising demand in this critical sector. The company also announces a positive turnaround in cash flow, achieving inflows of approximately $45.8 million in Q4 2024, compared to outflows of $60.8 million a year prior. For the full year, Natera reports positive cash inflows of $86.3 million, a remarkable recovery from cash outflows of $267.1 million in 2023.

As Natera prepares to present its results at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, the company is poised to discuss its strategies and future growth prospects further. Complete financial results will be unveiled during its earnings call in February 2025, providing additional insights into its operational performance and market positioning.

Overall, Natera’s recent performance underscores its leadership in the genetic testing arena, driven by innovative products and a growing demand for oncology testing. The company's ability to significantly improve both revenue and cash flow positions it well for continued success in the rapidly evolving landscape of genetic diagnostics.